Abstract: Disclosed are methods and reagents for the enzymatic measurement of short-chain fatty acids, having 3 to 6 carbon atoms, in a sample. Methods include the use of recombinant butyrate kinases from multiple species, combined various reagents that includes ATP, to detect butyric acid in different types of samples via measurement of ATP consumption. Disclosed also are the reagents themselves.

Abstract: Disclosed is an enzymatic measurement method comprising: contacting butyric acid in a sample, adenosine triphosphate (ATP), and butyrate kinase to produce adenosine diphosphate (ADP); and measuring the produced ADP.

Abstract: Disclosed is a method for assisting diagnosis of risk of progression of diabetic nephropathy, comprising measuring the urinary apolipoprotein E (ApoE) concentration of a patient with diabetic nephropathy showing a urinary albumin/Cr ratio of 30 mg/gCr or more, and determining that the patient has a high risk of progressing diabetic nephropathy when the value of urinary ApoE concentration is equal to or greater than a predetermined threshold value.

Abstract: Disclosed is a method for measuring urinary apolipoprotein E (ApoE) concentration of a diabetic patient with stage 1 diabetic nephropathy, decreased value of urinary ApoE concentration indicating the patient has a high risk of progressing to stage 2 or higher diabetic nephropathy.

Abstract: The object of the present invention is to provide a method for more accurately assaying the enzyme activities of mCK isozymes and a method for separately assaying the enzyme activities of CK isozymes by separately assaying the enzyme activities of ubiquitous mCK (umCK) and sarcomeric mCK (smCK). The above object is attained by an assay using an antibody that specifically recognizes umCK protein. In addition, other anti-mCK antibodies (e.g., anti-smCK antibody) and/or anti-human CK-M-inhibiting antibody can also be used. The above antibody is a polyclonal antibody or a monoclonal antibody. As a result of these antibodies, a monoclonal antibody (U1-1881) that is capable of specifically recognizing human umCK and is produced by a hybridoma having a deposition number of FERM BP-8342 is provided.

Abstract: Effective stabilizing amount at least of one antioxidant is added to a composition containing an esterase and surfactant(s).

Abstract: Effective stabilizing amount at least of one antioxidant is added to a composition containing an esterase and surfactant(s).

Abstract: The object of the present invention is to provide a method for more accurately assaying the enzyme activities of mCK isozymes and a method for separately assaying the enzyme activities of CK isozymes by separately assaying the enzyme activities of ubiquitous mCK (umCK) and sarcomeric mCK (smCK).

Abstract: A convenient means of examining nephropathy is provided. Paying attention to fat granules contained in urinary lipomicrons and oval fat which are observed in association with nephropathy, it is found out that the contents of lipoproteins or analogs thereof or constituents of the same contained in these substances significantly indicate relevance to nephropathy, thereby completing the above-described examination means.

Abstract: A method for measuring the activity of creatine kinase MB (CK-MB) isozyme which is accurate, high in specificity, convenient, by inhibiting the activity of a mitochondria-localized creatine kinase (mCK) isozyme to avoid the influence of mCK and a measurement reagent therefor are provided.

Abstract: A method for measuring the activity of creatine kinase MB (CK-MB) isozyme which is accurate, high in specificity, convenient, by inhibiting the activity of a mitochondria localized creatine kinase (mCK) isozyme to avoid the influence of mCK and a measurement reagent therefor.

Abstract: The problems of the present invention are to provide a simple and convenient means for the examination of renal failure and to provide a method for the measurement of a lipid component in urine utilizing the said examining means.

Abstract: By a process comprising inhibiting LDH2, LDH3, LDH4 and LDH5 in a sample with a protease in the presence of a protein-denaturating agent and then determining LDH1 remaining uninhibited, LDH1 in the sample is easily determined.

Abstract: A method for assaying biological specimens for substances contained in the components of each specimen by the use of one or more kinds of calixarenes; and a reagent comprising one or more kinds of calixarenes. The method utilizes complexes formed by calixarenes and the components of biological specimens, and makes it possible to assay biological specimens for substances contained in the components of each specimen, for example, for cholesterol contained in high-density lipoprotein (HDL), without preliminary separation from the other components of the biological specimen. The method can be conducted by easy and simple operations and lessen measurement errors or problems caused by man, and permits continuous measurement with general-purpose automatic analyzing apparatuses and multi-channel measurement together with other test items.

Abstract: The present invention relates to a method for determining a slight amount of NADH or XTP which is present in a solution, with high sensitivity by the use of an NADH kinase specific for NADH by utilizing a cycling reaction, and this method permits highly sensitive determination of NADH without any influence of NAD.sup.+ and hence is useful for diagnoses of diseases and the like.

Abstract: A glutamic-oxaloacetic transaminase (GOT) isozyme assay, which comprises selectively inhibiting s-GOT in a sample such as serum or plasma by proteinase K, optionally an excess amount of proteinase K by a protease inhibitor and then determining m-GOT remaining intact, is described.